Trials / Unknown
UnknownNCT05792293
Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity
Detailed description
The study participants are female patients with breast cancer receiving Anthracycline based chemotherapy. They will be divided into 2 groups , the first group will receive 40 mg oral atorvastatin through out the study , while the other group will receive a placebo. Full echocardiographic study including 3D echocardiography will be done to all patients before starting their chemotherapy and after 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin 40 Mg Oral Tablet | 40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
- First posted
- 2023-03-31
- Last updated
- 2023-04-06
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05792293. Inclusion in this directory is not an endorsement.